Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides
“Modified Factor X polypeptides may represent an attractive opportunity for broad coagulation control,” said
Factor X is a clotting factor that has the potential to be used as a “universal procoagulant.” Once activated to Factor Xa, it activates the final common pathway of coagulation proteins, leading to the formation of a blood clot. Because of its downstream clotting pathway activity, a safe and effective Factor Xa product could potentially treat hemophilia, blood loss in trauma and surgery in individuals with normal coagulation systems, and those who are bleeding as a result of taking anti-platelet agents or anticoagulants. In preclinical studies, Catalyst has identified Factor Xa variants that have demonstrated superiority to competing Factor Xa candidates in clinical development.
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential for Catalyst’s product candidates, including its Factor Xa variants, to treat hemophilia, blood loss in trauma and surgery in individuals with normal coagulation systems, and those who are bleeding as a result of taking anti-platelet agents or anticoagulants. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that human trials will not replicate the results from animal studies, that potential adverse effects may arise from the testing or use of the Company’s products, including the generation of antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018, along with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
LifeSci Public Relations
Source: Catalyst Biosciences, Inc.